PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-224315.95%
Both yoy net incomes decline, with GNPX at -17.92%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
418.75%
D&A growth of 418.75% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
2984.50%
SBC growth while GNPX is negative at -51.17%. John Neff would see competitor possibly controlling share issuance more tightly.
29070.41%
Well above GNPX's 193.21% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5571250.00%
A yoy AP increase while GNPX is negative at -231.79%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
12125.42%
Growth well above GNPX's 214.13%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
753.88%
Growth of 753.88% while GNPX is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-298628.16%
Negative yoy CFO while GNPX is 7.14%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-260.15%
Negative yoy CapEx while GNPX is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-260.15%
We reduce yoy invests while GNPX stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.